
    
      This is an international, multicenter, open-label, long-term safety study of ZX008 in
      pediatric and young adult subjects with Dravet syndrome who participated in one of the core
      studies (ZX008-1501 and ZX008-1502) and are candidates for continuous treatment for an
      extended period of time. This trial will consist of a 36-month Open-Label Extension (OLE)
      Treatment Period and a 2-week Post-Dosing Period.
    
  